AASLD-Liver Learning 2011:New Hepatitis C Treatments

Wednesday, November 30, 2011

AASLD-Liver Learning 2011:New Hepatitis C Treatments

The Liver Meeting® 2011 Educational Webcast of selected sessions

If you haven't yet explored the "LiverLearning" section available @ the AASLD web site you're missing out on the November meeting webcasts, video podcasts, abstracts and more. Free registration is required, it's quick and painless folks, start the process by clicking Here.
Once that is accomplished, check out some of the topics and programs available below .

View Complete list of selected sessions by clicking here

Access -50 Webcasts ,783 ePosters ,1229 Abstracts ,50 Video Podcasts
31 PPT Shared Files at LiverLearning

New Treatment Paradigms
by David R. Nelson

2011-11-07

Preparing the HCV Patient for Treatment
by Andrew Muir

2011-11-07

How direct-acting antivirals (DAA) Work and Their Limitations
by Raymond Chung

2011-11-07

Hepatitis Debrief

Dr. Gregory Everson
75 slide(s) – English
2011-11-08

Complications of Cirrhosis

HCV: Diagnosis and Natural History - 23 posters(s)
A 20-year cohort study on the natural history of untreated hcv infection in rural chinese plasmaphoresis donors
Jinyu Ren
2011-11-04

View Complete List of selected sessions
Free registration required
Register Here

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities, editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"

Latest Update Feb 12, 2019

Lancet Study:

Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C

These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy
Rebuttal over Cochrane Review of DAAs
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.